US20110039254A1

US20110039254A1 - Chromosomal Insertion of Gfp Into Bacteria For Quality Control

Info

Publication number: US20110039254A1
Application number: US11/662,801
Authority: US
Inventors: Leonardo B. Pinheiro; Peter Bergquist; Moreland Gibbs; Graham Vesey
Original assignee: MACQUARRIE UNIVERSITY; BTF Pty Ltd
Current assignee: MACQUARRIE UNIVERSITY; BTF Pty Ltd
Priority date: 2004-09-14
Filing date: 2005-09-12
Publication date: 2011-02-17
Also published as: US9309300B2; US20130065297A1; WO2006029449A1

Abstract

An isolated mutated green fluorescent protein (gfp) gene for chromosomal insertion into a bacterium, wherein the gene is capable of being expressed in bacteria and produce sufficient fluorescence under illumination from a UV lamp in a bacterial colony to be seen by the naked eye. A gene cassette for inserting a gene into a chromosome.

Description

TECHNICAL FIELD

The present invention is directed to methods for producing labelled cells, particularly visibly fluorescent bacteria suitable for use as quality control strains in microbiological or biological testing.

BACKGROUND

Microbiology testing laboratories maintain in-house culture collections of microorganisms for quality control purposes. These microorganisms are known as quality control (QC) strains and are used as reference standards and for quality control of the testing methods. Samples that are known to be free of contamination are often spiked with a QC strain and this spiked sample is then processed through the test method. A positive result from the spiked sample validates the testing method. The QC strains are also used to quality control media that is used to grow microorganisms. The media is inoculated with the QC strain and the growth is observed.
Traditionally these quality control checks that are performed with QC strains are qualitative. Recently, however, regulatory authorities such as ISO have begun enforcing quantitative quality control checks.
One problem that microbiology laboratories face is the issue of cross contamination. Laboratories can inadvertently contaminate a real sample with a QC strain. This results in a false positive result, which can have enormous implications such as unnecessary product recalls or incorrect diagnosis of disease.
In order to help with identifying instances of cross contamination, laboratories try to use species of bacteria as QC strains that are rarely detected in their samples. For example, in Australia Salmonella salford is used as a QC strain because it is rarely detected in clinical, food or environmental samples. When a laboratory detects Salmonella, tests are performed to check that the Salmonella detected is not Salmonella salford. If it does prove to be Salmonella salford then the validity of the result is questioned.
The use of rare species such as Salmonella salford as QC stains does help to identify cross contamination problems, however, confirming the identity of the strain that has been detected takes time. Typically, this confirmation takes between one and three days. In some instances, the confirmation has to be performed by a specialist laboratory. These lengthy delays can have serious implications. For example, a product recall may be delayed for several days during which time consumers would be exposed to the risk of infection.
A further problem with the use of rare species as QC strains is that the rare species may have biochemical or physiological properties that are different to those of the commonly isolated organisms. For example, Salmonella salford does not grow well on some media that are routinely used to isolate Salmonella from food, whereas the commonly isolated Salmonella such as Salmonella typhyimurium do grow well on these media. Salmonella salford is therefore not a suitable QC strain for these culture media.
In an attempt to address this problem, the present inventors hypothesized that it would be extremely useful to have QC microorganisms that form colonies on agar plates are fluorescent when viewed by the naked eye with illumination from a UV lamp.
The genetic modification of microorganisms with fluorescent genes has been widely studied (GFP: Properties, Applications, and Protocols (1998) Chalfie M, Kain S. Wiley-Liss, New York, USA). The most commonly employed gene for a fluorescent protein is the green fluorescent protein (GFP) gene (gfp) from the jellyfish Aequorea Victoria. Genes encoding other fluorescent proteins have also been isolated from other coelenterates.
Fluorescent bacteria have been created previously by incorporating a gfp gene into a plasmid and inserting the plasmid into the bacteria. The plasmid normally contains an antibiotic resistant gene that allows the bacteria to be grown on antibiotic containing media. The antibiotics kill any bacteria that do not retain the plasmid. These plasmid-containing strains only retain their fluorescence when grown on media that contain antibiotics.
An advantage of plasmid-carrying strains is that several hundred copies of the plasmid are normally present within a bacterial single cell. This means that several hundred copies of the fluorescence gene can be placed within each cell to create cells that are very fluorescent.
Plasmid instability can be a major problem in culturing bacteria, particularly if the cultures go through many generations by passaging. The resulting effects are loss of expression of any plasmid-encoded phenotype because of the build-up of non-productive plasmid-free cells. Plasmid instability can be due to segregational instability and/or structural instability. Segregational instability is the loss of plasmid from one of the daughter cells during cell division because of defective partitioning. Structural instability is attributed to deletions, insertions and rearrangements in the plasmid DNA, resulting in the loss of expression of the encoded phenotype. Plasmid stability is influenced by the vector and host genotypes, vector copy number, and the origin and size of foreign DNA have been observed to affect plasmid stability. Plasmid stability is also a function of physiological parameters that affect the growth rate of the host cell, which include pH, temperature, aeration rate, medium components and heterologous protein accumulation.
Plasmid instability is undesirable in the production of bacterial strains for quantitative QC methods, as consistent expression of the QC phenotype is paramount. Consistent expression could be achieved by irreversibly integrating the genes encoding the fluorescent phenotype into the host genome to ensure long-term stability and expression of the gene product. Ideally, only a single copy of the marker gene should be integrated into the bacterial chromosome as this reduces the likelihood of gene instability resulting from homologous recombination-mediated gene excision.
The preferred requirement of a single copy fluorescence gene in the bacterial genome means that achieving sufficient fluorescence maybe challenging. In comparison, the use of a plasmid containing strain allows several hundred copies of the fluorescence gene to be present. To ensure that a high level of fluorescence is achieved with a single copy on the genome a transcriptional promoter should be chosen that is powerful enough to produce visible fluorescence.
It has been found to be difficult to incorporate genes into a bacterial chromosome and still obtain the required selective or characteristic genotype.
The present inventors have developed several strong bacterial promoter systems for the expression of fluorescent phenotypic markers in microbial cells.

SUMMARY OF INVENTION

The present inventors have devised methods which surprisingly allow for the preparation of microorganisms that are fluorescent even when passaged multiple times on media that does not contain antibiotics or other selective pressures.
In a first aspect, the present invention provides an isolated mutated green fluorescent protein (gfp) gene for insertion into the chromosome of a bacterium, the gene is capable of being expressed and produce sufficient fluorescence under illumination from a UV lamp in a bacterial colony to be seen by the naked eye.
Mutations at nucleotides positions 1492, 1493 (Ser72Ala), 1737 (Met153Thr) and 1766 (Val163Ala), as set out in FIG. 3, in the wild-type gfp gene, or mutations for synonymous codons which change the same amino acid positions (Ser72Ala, Met153Thr and Val163Ala), are encompassed by the present invention.
In a preferred form, the mutated gfp gene has a nucleic acid sequence from bases 1524 to 2240 as set out in FIG. 4 (SEQ ID NO 6).
The mutated gene can be preferably optimized for different bacteria. The gene is particularly adapted for chromosomal insertion and expression in bacteria.
In a second aspect, the present invention provides an isolated green fluorescent protein (GFP) expressed by the mutated gfp gene according to the first aspect of the present invention.
In a third aspect, the present invention provides an isolated mutant green fluorescent protein (GFP) capable of producing sufficient fluorescence under illumination from a UV lamp in a bacterial colony to be seen by the naked eye.
Preferably, the isolated mutant GFP is selected from a protein having one or more mutations of mutant GFP01, mutant GFP02, mutant GFP03, mutant GFP07, mutant GFP10, mutant GFP15, mutant GFP16, mutant GFP20, mutant GFP21, mutant GFP22, mutant GFP26, mutant GFP27, mutant GFP37, mutant GFP43, mutant GFP44, mutant GFP53, mutant GFP54, or mutant GFP55 as defined below in Table 2.
Preferably, the isolated mutant GFP is selected from mutant GFP01, mutant GFP02, mutant GFP03, mutant GFP07, mutant GFP10, mutant GFP15, mutant GFP16, mutant GFP20, mutant GFP21, mutant GFP22, mutant GFP26, mutant GFP27, mutant GFP37, mutant GFP43, mutant GFP44, mutant GFP53, mutant GFP54, or mutant GFP55 as defined below in Table 2.
In a preferred from, the isolated mutant GFP has an amino acid sequence as set out in SEQ ID NO 4.
In a fourth aspect, the present invention provides an unrepressed or constitutive gene cassette for providing a gene to a chromosome comprising an endogenous gene under the control of the very strong bacteriophage lambda promoter left (P_L) and one or more transposon elements. It will be appreciated that the cassette can incorporate other suitable transcriptional promoters to allow expression of a gene product in a cell or bacterium.
In one form, the cassette has a nucleotide sequence from 1 to 1278 and 1996 to 2007 substantially as shown in FIG. 3, wherein the gene is inserted between positions 1728 and 1996.
In another form, the cassette has a nucleotide sequence from 1 to 1523 and 2241 to 2326 substantially as shown in FIG. 4 (SEQ ID NO 4), wherein the gene is inserted between positions 1523 and 2241.
In a preferred form, the cassette has a nucleotide sequence from 1 to 309 and 1027 to 1032 substantially as shown in FIG. 5 (SEQ ID NO 7), wherein the gene is inserted between positions 310 and 1026 (SEQ ID NO 8).
The cassette is suitable of inserting any gene, endogenous or exogenous, mutant or native into the chromosome of a bacterium or cell. Examples include but not limited to genes encoding green fluorescent protein (gfp), red fluorescent protein, yellow fluorescent protein or any unmodified or modified versions of known fluorescent proteins. Examples also include genes that encode proteins capable of catalysing the production of calorimetric or fluorescent pigments, including but not limited to carotenoids, indole or indirubin.
Preferably, the gene is a green fluorescent protein (gfp) gene. More preferably, the gene is a mutant gfp gene.
The present inventors have demonstrated the suitability of the cassette by developing bacteria having enhanced fluorescence by inserting a green fluorescent protein (gfp) gene into the chromosome of the bacteria. It will be appreciated that the cassette can be used for any suitable gene to allow expression of the gene product in a cell or bacterium.
In a fifth aspect, the present invention provides a bacterium or cell containing a gene cassette according to the fourth aspect of the present invention.
In a sixth aspect, the present invention provides an unrepressed or constitutive gene cassette for providing a green fluorescent protein (gfp) gene to a bacterium comprising a gfp gene under the control of a strong promoter and one or more transposon elements.
Preferably, the gene is under the control of the very strong bacteriophage lambda promoter left (P_L).
In one form, the cassette is substantially as shown in FIG. 3 (SEQ ID NO 1).
In another form, the cassette is substantially as shown in FIG. 4 (SEQ ID NO 4).
Preferably, the cassette is as substantially as defined in FIG. 5 (SEQ IN NO 7).
In a preferred form, the mutant gfp gene substantially as shown in nucleotide bases 310 to 1026 of FIG. 5 (nucleotide bases 310 to 1026 of SEQ ID NO 7).
The cassette is particularly suitable for providing a mutant green fluorescent protein to the chromosome of a bacterium.
It will be appreciated that similar results could be achieved with other forms of GFP, possibly even the wild type GFP would be sufficiently fluorescent when used with the gene cassette according to the present invention.
In a seventh aspect, the present invention provides a bacterium or cell containing the mutated GFP gene according to the first aspect of the present invention or a gene cassette according to the fourth aspect of the present invention.
The bacterium can be any suitable bacterium such as Acinetobacter lwoffii, Aeromonas hydrophila, Aspergillus niger, Bacillus cereus, Bacillus subtilis, Campylobacter coli, Campylobacter jejuni, Candida albicans, Citrobacter freundii, Clostridium perfringens, Clostridium sporogenes, Edwardsiella tarda, Enterobacter aerogenes, Enterobacter cloacae, Enterococcus faecalis, Escherichia coli, Escherichia coli 0157, Haemophilus influenzae, Klebsiella pneumoniae, Klebsiella aerogenes, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus fermentus, Legionella pneumophila, Listeria innocua, Listeria ivanovii, Listeria monocytogenes, Meth. Resist. Staph. Aureus, Neisseria gonorrhoeae, Proteus rettgeri, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Pseudomonas cepacia, Pseudomonas fluorescens, Rhodococcus equi, Salmonella abaetetuba, Saccharomyces cerevisiae, Salmonella salford, Salmonella menston, Salmonella sofia, Salmonella Poona, Salmonella typhimurium, Salmonella poona, Serratia marcescens, Shigella sonnet, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes, Vibrio parahaemolyticus, Yersinia enterocolitica, Zygosaccharomyces rouxii.
Preferably, the bacterium is Escherichia col. More preferably, the E. coli is NCTC 9001 or NCTC 12241 as herein defined.
Preferably, the bacterium is Salmonella sp. More preferably, the Salmonella sp is Salmonella typhimurium or Salmonella abaetetuba as herein defined.
Preferably, the bacterium is Listeria sp. More preferably, the Listeria sp is L. monocytogenes.
Examples of bacteria containing a mutated GFP gene or cassette according to the present invention have been deposited with the Australian National Measurement Institute on 13 Sep. 2004 under Accession Nos NM04/42817, NM04/42818, NM04/42819 and NM04/42820.
The identity of the deposited bacteria are as follows:

NM04/42817 is E. coli NCTC12241
NM04/42818 is Salmonella abaetetuba
NM04/42819 is Salmonella typhimurium
NM04/42820 is E. coli NCTC9001

The cell can be any suitable cell including prokaryotic or eukaryotic. Examples of non-bacterial cells include fungal and yeast cells such as Candida albicans, Zygosaccharomyces rouxii or Aspergillus niger.
In a eighth aspect, the present invention provides a modified bacterium containing a mutated gfp gene or cassette selected from NM04/42817, NM04/42818, NM04/42819 or NM04/42820.
In a ninth aspect, the present invention provides use of a bacterium according to the seventh or eighth aspects of the present invention having fluorescence as a detectable marker.
Preferably, the use is as a laboratory QC strain.
The fluorescent bacteria are suitable for use as internal quality controls as described in WO 01/09281, incorporated herein by reference.
The fluorescent bacteria can be used for tracking purposes. Examples of this use include: studies on the transport of cells within the environment; tracking of cells within water treatment plants; studies on gene exchange in the environment.
The fluorescent bacteria can be used to leak test biological safety equipment such as safety cabinets and respirators.
The fluorescent bacteria can be used to test the efficiency of any process that is designed to remove or inactivate bacteria. Examples include water filters, UV disinfection methods, chemical disinfection methods and heat treatment.
The fluorescent bacteria are also suitable for use in materials testing methods. Examples of this include the testing of water fittings to show that they do not support the growth of microorganisms.
The fluorescent bacteria are suitable for use in a sewage treatment process. Sewage treatment relies on the presence of specific bacteria such as nitrifying bacteria. Adding fluorescent nitrifying bacteria would allow accurate monitoring of cell density of nitrifying bacteria within the sewage treatment process.
Bacteria are commonly used to control non-desirable bacteria. Bacteria are added to a process or a product to out-compete non-desirable bacteria. An example of this is the control of Salmonella on chickens. Chickens are routinely treated with Salmonella cells from a specific strain of Salmonella, known as Salmonella sofia, that is not infectious to humans. The Salmonella sofia colonises the chickens and out-competes more harmful strains of Salmonella. At present there is not a simple method to check that the chickens are colonised with Salmonella sofia. By treating the chickens with a fluorescent form of Salmonella sofia the level of Salmonella sofia on a chicken or on processed chicken meat could be easily monitored by measuring fluorescence. Fluorescence bacteria could be used for any process that requires the monitoring of introduced bacteria.
The bacterium can be supplied as a culture or in the form of a BioBall™ (BTF Pty Ltd, Australia) according to U.S. Pat. No. 6,780,581 or WO 03/020959.
The present inventors have found that the fluorescence is substantially stable when the bacteria are passaged multiple times. Antibiotics, for example, are not required to keep the fluorescence gene within the bacteria.
The mutated GFP gene results in brighter fluorescence in E. coli, for example, compared with a wildtype GFP gene expressed in a plasmid in an equivalent strain of E coli. Not being bound by theory, the inventors believe that brighter fluorescence may be due to rapid maturation of the green fluorescence protein in bacteria. As the mutations have slightly changed the structure of the protein, it is likely that this changed structure matures more rapidly in bacteria than the wild type GFP.
Although other mutants of the GFP gene have been made and disclosed in the prior art, all these mutants have fluorescence excitation and emission properties different to the wild type GFP. The GFP mutant according to the present invention, however, has substantially the same excitation and emission spectra as the wild type GFP.
Although other forms of tagging bacteria on the chromosome have been published previously, the tagging methods enable the bacteria to grow on certain media or selective conditions.
Throughout this specification, unless the context requires otherwise, the word “comprise”, or variations such as “comprises” or “comprising”, will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed in Australia prior to development of the present invention.
In order that the present invention may be more clearly understood, preferred embodiments will be described with reference to the following drawings and examples.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1. A. Diagrammatic representation of oligonucleotide primer binding positions relative to the proposed gfp gene cassette. B. Diagrammatic representation of the two PCR products generated with oligonucleotide primer pairs as marked, for construction of the gfp gene cassette, containing the wild-type gfp gene, by overlap extension PCR. C. Diagrammatic representation of the five PCR products generated with oligonucleotide primer pairs as marked, for construction of the complete gfp gene cassette, containing modified gfp genes, by overlap extension PCR. D. Diagrammatic representation of the structure of the gfp gene cassette showing the position and orientation of the clts857 and gfp genes, and the positions of the lambda P_Rand P_Loperators. The relative positions of the codons within gfp that are altered by site directed mutagenesis are marked by their corresponding amino acid changes.

FIG. 2. A. Structure of the pEntransposon-CamR plasmid and the gfp gene cassette. Transposon arms are labeled Mu. The pBR322 origin of replication is labeled ori. B. Structure of the plasmid generated following ligation to the gfp gene cassette into pEntransposon-CamR at EcoRI and SalI restriction sites. Arrows indicate relative binding positions and orientation of oligonucleotides PENTGWF and GFPGWR used for genomic walking PCR. C. Structure of the plasmid shown in B. following deletion of the clts857 gene and the lambda P_Rpromoter by digestion with EcoRV and SmaI, followed by recircularisation by blunt-end ligation. Arrows indicate relative binding positions and orientation of oligonucleotides PENTGWF and GFPGWR used for genomic walking PCR. D. Structure of the gfp gene cassette once excised from the plasmid shown in C. Arrows indicate relative binding positions and orientation of oligonucleotides PENTGWF and GFPGWR used for genomic walking PCR.

FIG. 3 shows a sequence map of the gfp gene cassette (SEQ ID NO 1) containing the wild-type gfp gene, showing the location of the major sequence elements as depicted in FIG. 1D. Key restriction sites are underlined. The lambda P_Roperators are underlined and marked R1-R3. The lambda P_Loperators are underlined and marked L1-L3. A translation of the lambda cl^ts857gene is shown underneath the DNA sequence (running in reverse orientation 17 to 730 bp SEQ ID NO 2). A translation of the gfp gene is shown underneath the DNA sequence (running in forward orientation 1279 to 1995 bp; SEQ ID NO 3).

FIG. 4 shows a sequence map of the gfp gene cassette (SEQ ID NO 4) containing the modified gfp gene, after deletion of the lambda cl^ts857gene and lambda P_Rpromoter. Key restriction sites are italicised. The lambda P_Loperators are underlined and marked L1-L3. Transposon arms are underlined (6-54 bp and 2273-2321 bp). Codons changed by site directed mutagenesis to generate the modified gfp gene are underlined and labelled. A translation of the chloramphenicol resistance gene is shown underneath the DNA sequence (278 to 937 bp; SEQ ID NO 5). A translation of the modified gfp gene is shown underneath the DNA sequence (1524 to 2240 bp; SEQ ID NO 6).

FIG. 5 shows a sequence map of the minimal gfp gene cassette (SEQ ID NO 7) containing the modified gfp gene and lambda P_Lpromoter. Key restriction sites are italicised. The lambda P_Loperators are underlined and marked L1-L3. Codons changed by site directed mutagenesis to generate the modified gfp gene are underlined and labelled. A translation of the modified gfp gene is shown underneath the DNA sequence (310 to 1026 bp; SEQ ID NO 8).

MODE(S) FOR CARRYING OUT THE INVENTION

EXAMPLE 1

The following example describes the creation of a GFP cassette, the creation of mutants of GFP that showed increased fluorescence in a plasmid within E. coli and the chromosomal integration of the mutant GFP and the wild type GFP into E. coli.

Construction of a Temperature Controlled GFP Gene Cassette

In an attempt to obtain visibly detectable levels of GFP in bacterial colonies, a gene cassette was constructed comprising a modified gfp gene under the control of the very strong bacteriophage lambda promoters right and left (P_Rand P_L), and the gene coding for lambda thermolabile cl^ts857repressor protein. The regulatory regions for the gfp gene cassette were obtained from the controlled expression vector pJLA602 (Schauder et al., 1987 Gene 52: 279-283) by PCR. The cl^ts857repressor protein tightly represses transcription from the lambda P_Rand P_Lpromoters when grown at temperatures below 37° C. Incubating growing cultures at 42° C. results in inactivation of the cl^ts857repressor protein resulting in high level transcription of genes placed immediately downstream of the lambda P_Lpromoter.
The modified gfp gene was constructed by site directed mutagenesis using overlapping sets of degenerate oligonucleotides to reconstruct the full length gfp gene with 6 modified codons positions. The modified sites and the selected residue alterations were chosen for their proven ability to improve the maturation and fluorescence of GFP in E. coli. The use of degenerate oligonucleotide primers resulted in the creation of a library of gfp genes that varied between 2 or 3 possible codons at each of the 6 chosen codon positions. The oligonucleotide primers are described below and are listed in Table 1. The binding positions of all oligonucleotide primers with respect to the gfp cassette are shown in FIG. 1A. The PCR products generated with said primers for reconstruction of the gfp cassette is shown in FIG. 1C. The complete gfp cassette is shown in FIG. 1D. The wild-type gfp gene was also placed into the cassette in the same manner for use as a control (see FIG. 1B).

TABLE 1

Name	Sequence	SEQ ID NO

gfpF0	5′-TTTTTTGAATTCTTATTTGTATAGTTCATC	9

gfpR1	5′-CTTTACTCATGGCAGTCTCCAGTTTGT	10

gfpF1	5′-GAGACTGCCATGAGTAAAGGAGAAGA	11

gfpF2	5′-ATGGTSTTCAATGCTTTKCRAGATACCCAGATCA	12
	TA

gfpF3	5′-AACTATATYTTTCAAAGATGACGGGA	13

gfpF4	5′-CAAACAAAAGAATGGAATCAAAGYTAACTTCAAA	14
	ATTAGA

gfpR0	5′-TTTTTTGAATTCTTATTTGTATAGTTCATC	15

gfpR2	5′-AAAGCATTGAASACCATAMSMGAAAGTAGTGACA	16
	AGT

gfpR3	5′-CTTTGAAARATATAGTTCTTTCCTGTA	17

gfpR4	5′-TTCCATTCTTTTGTTTGTCTGCCRTGATGTATAC	18
	ATTGTGT

gfpEnt	5′-CCAGTTTGCTCAGGCTCT	19

T7promppf1	5′-GGGGAATTCTTAATACGACTCACTATAGAAGGAG	20
	ATATACATAT GGCCTCCGAGAACGTCATCA

Rfppr1	5′-GGGGGGGTCGACCTACAGGAACAGGTGGTGG	21

PENTGWF	5′-TGATCTTCCGTCACAGGT	22

GFPGWR	5′-GTAACAGCTGCTGGGATT	23

The oligonucleotides primers used for the PCR amplification of the gfp gene cassette regulatory regions were as follows:

gfpF0, 5′-TTTTTTGAATTCTTATTTGTATAGTTCATC-3′ (SEQ ID NO 9), a primer to amplify bacteriophage lambda cl^ts857/P_R/P_Lregion from pJLA602. This primer incorporates a SalI site for directional ligation of the cassette into a plasmid vector.
gfpR1, 5′-CTTTACTCATGGCAGTCTCCAGTTTGT-3′ (SEQ ID NO 10), a primer to amplify and overlap the lambda cl^ts857repressor gene/P_R/P_Lwith the gfp gene.

Variants of the GFP were generated by oligonucleotide directed mutagenesis of the wild type gfp gene. Mutagenic PCR amplifications of the GFP gene were performed using combinations of degenerate and non-degenerate oligonucleotide primers.
For the site directed mutagenesis and PCR amplification of the gfp gene the following oligonucleotides were used:

gfpF1, 5′-GAGACTGCCATGAGTAAAGGAGAAGA-3′ (SEQ ID NO 11), a primer to amplify and overlap lambda cl^ts857/P_R/P_L/atpE with the gfp gene.
gfpF2, 5′-ATGGTSTTCAATGCTTTKCRAGATACCCAGATCATA-3′ (SEQ ID NO 12), a degenerate primer for the amplification and mutagenesis of gfp. This primer introduces three possible point mutations, Ser65Ala or Ser65Gly, Val68Leu, and Ser72Ala into the gfp gene.
gfpF3, 5′-AACTATATYTTTCAAAGATGACGGGA-3′ (SEQ ID NO 13), a degenerate primer for the amplification and mutagenesis of gfp. This primer introduces a single possible point mutation, Phe99Ser, into the gfp gene.
gfpF4, 5′-CAAACAAAAGAATGGAATCAAAGYTAACTTCAAAATTAGA-3′ (SEQ ID NO 14), a degenerate primer for amplification and mutagenesis of gfp. This primer introduces a single possible point mutation, Met153Thr, into the gfp gene.
gfpR0 primer 5′ TTTTTTGMTTCTTATTTGTATAGTTCATC-3′ (SEQ ID NO 15), a primer to amplify the gfp gene. This primer incorporates an EcoRI restriction site for directional ligation of the cassette into a plasmid vector.
gfpR2, 5′-AAAGCATTGAASACCATAMSMGAAAGTAGTGACAAGT-3′ (SEQ ID NO 16), a degenerate primer for the amplification and mutagenesis of the gfp gene. This primer introduces two possible point mutations, Ser65Ala or Ser65Gly and Val68Leu, into the gfp gene.
gfpR3 primer 5′-CTTTGAAARATATAGTTCTTTCCTGTA-3′ (SEQ ID NO 17), a degenerate primer for amplification and mutagenesis of the gfp gene. This primer introduces a single possible point mutation, Phe100Ser, into the gfp gene.
gfpR4 primer 5′-TTCCATTCTTTTGTTTGTCTGCCRTGATGTATACATTGTGT-3′ (SEQ ID NO 18), a degenerate primer for amplification and mutagenesis of the gfp gene. This primer introduces a single possible point mutation, Met153Thr, into the gfp gene.

For amplification and mutagenesis of the gfp gene, plasmid DNA from the pGFP vector (Clontech) was used as template DNA. PCR amplification of the gfp gene, the regulatory regions and the gfp gene segments contained 1× PCR Gene Amp buffer; 200 μM of each of the four deoxyribonucleotide triphosphate (dATP, dTTP, dCTP, dGTP); 0.3 μM of each oligonucleotide primer (forward and reverse); AmpliTaq-Gold Polymerase (Applied Biosystems) and approximately 10 ng of template DNA in a 50 μl reaction volume. PCR reactions were performed in a Gene Amp PCR system 2400 (Applied Biosystems) programmed as follows: 95° C. for 10 min, (95° C. 30 sec, 55° C. 30 sec, 72° C. 1 min) repeated for 30 cycles, and a final cycle at 72° C. for 5 min. PCR products originating from amplification reactions of the regulatory regions and the four different segments of the mutant gfp gene were visualized by agarose gel electrophoresis and the DNA purified using a QIAquick gel extraction kit (Qiagen Inc).
Assembly of the gfp gene and regulatory regions into the gfp gene cassette were performed by overlap extension PCR (Ho et al., 1989 Gene 77:51-59). Optimization of PCR conditions was required for successful assembly of the gfp gene cassette. Best results for the assembly of gfp gene segments into an full length gene were obtained by first performing a primerless overlap extension step with a programmed decrease in the annealing temperature (1° C. per PCR cycle) followed by addition of oligonucleotides and a further PCR step. The PCR reagents used were the same as that described above, except for combining and using the 4 gfp gene cassette segments, each at approximately 10 ng, as template DNA in a 50 μl PCR reaction. The relative positions of primers with respect to the major elements in the GFP cassette are shown in FIG. 1A. The relative positions of PCR products amplified and used for overlap extension reassembly of the GFP cassette are shown in FIG. 1B. The final complete GFP cassette is depicted in FIG. 1C.
A PCR for the assembly of the wild type gfp gene and the upstream lambda regulatory regions into a single cassette was performed as follows: a primerless overlap extension stage (95° C. for 10 min, 95° C. 30 sec, 50° C. down to 35° C. over 15 cycles with 1° C. decrease per cycle for 30 sec each cycle), followed by addition of primers (gfpF0 and gfpR0) and a second PCR stage comprising 95° C.—30 sec, 55° C.—30 sec, 72° C.—1 min, repeated for 30 cycles, and a final cycle at 72° C. for 5 min.
A PCR for the recombination of the four mutant GFP gene segments into a pool of selectively mutated full length gfp genes was as follows: a primeness overlap extension stage (95° C. for 10 min, 95° C. 30 sec, 50° C. down to 30° C. over 20 cycles with 1° C. decrease per cycle for 30 sec each cycle), followed by addition of primers (gfpF1 and gfpR0) and a second PCR stage of 95° C. 30 sec, 55° C. 30 sec, 72° C. 1 min, repeated for 30 cycles. After amplifying the assembled mutant gfp gene, a second PCR reaction was carried out using the same conditions used for the assembly of the wild type gfp gene, but in this case using the reassembled mutant gfp gene and the upstream regulatory regions to reassemble the entire mutant gfp gene cassette.
The complete sequence of the mutated gfp gene cassette, including gene translations, promoter elements, and mutation positions, is given in FIG. 3. Similarly, The complete sequence of the wild-type gfp gene cassette is given in FIG. 4.

Creation of GFP Mutants

The gfp gene cassette was designed to include two unique restriction enzyme sites, SalI at the 5′end and EcoRI at 3′end. These restriction sites were used for direction ligation of the mutated gfp gene cassette into the multiple cloning site of the pEntranceposon CmR vector (Finnzymes). The pEntranceposon CmR vector is a high copy number plasmid constructed by replacing the multiple cloning site of the high copy number plasmid pUC19 with the bacterial phage Mu transposon, and the chloramphenicol resistance gene (CamR).
PCR product comprising the complete mutant gfp gene and the plasmid vector pEntranceposon CamR were digested with SalI and EcoRI restriction enzymes (MBI Fermentas). The digested DNA fragments were visualized and purified from agarose gel using a QIAquick gel Extraction kit (Qiagen). The digested mutated gfp gene cassette and pEntranceposon CamR vector were ligated together and transformed into E. coli DH5α to generate a library of clones containing gfp genes randomly mutated at 6 selected positions (see FIG. 2). Similarly, the wild type GFP gene cassette was ligated to the digested pEntranceposon CamR vector and transformed into E. coli DH5 alpha.
Transformed cells were plated onto Luria Bertani (LB) agar media plates containing 25 μg/ml of chloramphenicol and incubated at 28° C. After 48 hours incubation, the incubation temperature was shifted to 42° C. for two to three hours for inactivation of the cl^ts857repressor protein and induction of GFP expression. Colonies expressing GFP were screened by visualization of fluorescence using a hand held ultraviolet lamp (UV 365 nm). A number of colonies expressing GFP appeared on the plates. Colonies originating from the mutant GFP gene construct showed visually detectable variation in GFP fluorescence intensity emitted from colonies and were graded accordingly.

Sequencing the Mutant GFP Clones

Five wild type GFP transformants and 18 mutant GFP transformants were selected following visual screening for fluorescence. Several of the mutant GFP transformants were significantly brighter than the wild type GFP transformants. The selected mutant GFP clones included the brightest fluorescing colonies as well as colonies showing intermediate and low intensity fluorescence. Single recombinant colonies were re-streaked to new LB plates containing 25 μg/ml of chloramphenicol. These cells were used for inoculation of 3 ml LB liquid media containing 25 μg/ml of chloramphenicol. Cultures obtained after overnight incubation at 28° C. with shaking were used for plasmid DNA extraction using QIAprep kits (Qiagen). Extracted plasmid DNA from the selected GFP clones was then used for nucleotide sequencing of the gfp gene cassette to determine the gfp genotype. Sequencing reactions (Big Dye terminator chemistry Applied Biosystems Inc) were performed using plasmid DNA extracted from GFP transformants. The oligonucleotide primers gfpF0 and gfpR1 were used for sequencing of the regulatory regions of GFP gene cassette, while gfpF1 and gfpR0 primers for sequencing of the GFP gene open reading frame within the GFP gene cassette. Sequencing results were analyzed using the GCG Wisconsin software package version 8 (Devereux J, Haeberli P, Smithies O, 1984, Nucleic Acids Res 12:387-395). Results from the nucleotide sequencing analysis were used for amino acid sequence alignment of wild type GFP and GFP mutants. A summary of amino acid changes identified in the GFP mutants is presented in Table 2.
Results from the sequencing analysis indicated that the most frequently occurring amino acid changes, Ser at position 72 to Ala, Met at position 153 to Thr and Val at position 163 to Ala, were found in the GFP mutants clones showing the brightest fluorescence intensity when visualized as colonies on plates illuminated with ultraviolet light (UV 365 nm). These mutants were considerably brighter than colonies that contained the wild type GFP.
The mutant gfp gene construct containing the three most frequent amino acid changes as well as wild type GFP gene construct were chosen for bacterial chromosomal integration experiments as described below. This plasmid was named pENTcIGFP (See FIG. 2B).

TABLE 2

Modified amino acid residues

Position

	65	68	72	99	153	163

	Ser	Val	Ser	Phe	Met	Val
wild type GFP	Ser	Val	Ser	Phe	Met	Val
mutant GFP01	Ser	Val	Ala	Phe	Thr	Ala
mutant GFP02	Ala	Val	Ala	Phe	Thr	Ala
mutant GFP03	Ser	Val	Ser	Phe	Thr	Ala
mutant GFP07	Ser	Val	Ala	Phe	Thr	Ala
mutant GFP10	Ser	Val	Ser	Phe	Thr	Ala
mutant GFP15	Ser	Val	Ala	Phe	Thr	Ala
mutant GFP16	Ser	Leu	Ala	Phe	Thr	Ala
mutant GFP20	Ser	Val	Ala	Phe	Thr	Ala
mutant GFP21	Ser	Leu	Ala	Phe	Thr	Ala
mutant GFP22	Ser	Val	Ser	Phe	Met	Ala
mutant GFP26	Ser	Leu	Ala	Phe	Thr	Ala
mutant GFP27	Ser	Leu	Ala	Ser	Met	Ala
mutant GFP37	Ser	Val	Ala	Phe	Thr	Ala
mutant GFP43	Ser	Val	Ser	Phe	Thr	Ala
mutant GFP44	Ser	Leu	Ala	Ser	Thr	Ala
mutant GFP53	Ser	Leu	Ala	Ser	Met	Ala
mutant GFP54	Ser	Val	Ser	Ser	Met	Val
mutant GFP55	Ser	Val	Ser	Ser	Thr	Val

Integration of GFP into the Chromosome of E. Coli

Integration of the gfp gene cassette into the E. coli DH5α genome was performed by insertion mutagenesis using bacteriophage Mu DNA transposition complexes (Lamberg et al., 2002 Appl Environ Microbiol 68: 705-712). This system was chosen as the transposon cassette does not include the gene encoding Mu transposase. Transposase enzyme is added to purified transposon DNA to form a transposition complex that is then transferred into bacterial cells by electroporation. The transposase mediates the integration of the transposon into the genome, effectively resulting in irreversible integration of the transposon and any included genes, into the bacterial chromosome.
Plasmid DNA of pEntranceposon vectors containing the GFP gene cassette were used for BglII restriction enzyme digests. The BglII digestion excises the transposon from the pEntranceposon vector. Digested plasmid DNA was separated using agarose gel electrophoresis and the pEntranceposon CamR transposon fragment containing the gfp gene cassette purified using a QIAquick gel Extraction kit (Qiagen Inc). Purified pEntranceposon DNA was used for transpososome assembly reactions.
Transpososomes are stable protein DNA complexes formed by the binding of MuA transposase protein into specific binding sites at each end of the transposon DNA.
Transpososome formation reactions were optimized by titration of the amount of pEntranceposon DNA against a fixed amount of MuA transposase enzyme (Finnzymes).
Reagents for transpososome assembly reaction mixtures (20 μl) included ˜6 pmol of MuA transposase, 50% glycerol, 150 mM of Tris-HCl (pH 6.0), 150 mM NaCl, 0.1 mM EDTA, and 0.025% (v/v) Triton X-100. Transpososome reactions were performed by adding ˜0.25 pmol to ˜1.0 pmol of pEntranceposon DNA containing the GFP gene cassette to the mixtures followed by incubating at 30° C. for 2-3 hours. Transpososome formation was visualized by electrophoresis on 2% agarose-TAE buffer gel containing 80 μg/ml of bovine serum albumen. Transpososome assembly reaction samples (1 μl) were loaded into the gel using 0.2 (v/v) of Ficoll 400 as loading buffer. After gel visualization, selected transpososome complexes were used for the transformation of electrocompetent E. coli DH5α cells.
Electrocompetent E. coli cells were prepared by growing 500 ml of culture in SOB medium at 37° C. with shaking to optical density at 600 nm of 0.8. Cells were then harvested by centrifugation at 4° C. and resuspended in 25 ml of ice-cold 10% glycerol four times consecutively, then resuspended in 1 ml of ice-cold 10% glycerol. Aliquots of 1 μl of transpososome reactions were used for electroporation of 40 μl electro-competent E. coli cells using a Genepulser (Bio-Rad) at the following settings: voltage 2.5 kV; capacitance 25 μF; resistance 200Ω (Bio-Rad 2-mm electrode spacing cuvettes). After electroporation 1 ml of SOC medium was added, incubated for 90 minutes, spread onto LB plates containing 25 μg/ml of chloramphenicol and incubated at 28° C. After 48 hours incubation at 28° C. cultures incubation temperature was shifted to 42° C. for two to three hours to induce GFP expression.
The few colonies that appeared on plates originated from integration of both mutant and wild type GFP gene cassette showed no fluorescence when illuminated with UV lamp. To verify if the integration of the GFP gene cassette was successful, PCR amplification reactions using gfpF1 and gfpR0 primers were carried using colonies growing on plates originating from electro-transformation of both mutant and wild type GFP transpososomes. Results were positive for the presence of the GFP gene in the colonies. Four selected positive colonies (both mutant and wild type GFP putative integrants) were grown overnight in liquid media (LB+chloramphenicol). After harvesting cultures by centrifugation, genomic DNA from ˜100 μg of cell paste was extracted using DNA extraction kit (Fast DNA, BIO 101 systems). Genomic DNA from two different isolates originating from both mutant and wild type GFP putative integrants were used for nucleotide sequencing using the system of analysis as described above. Oligonucleotide primers gfpF0 gfpR1 and gfpF1 gfpR0 were used for sequencing of both regulatory and open reading frame within the GFP gene cassette.
The above results confirmed the integration of intact GFP gene cassette sequence in the genomic DNA of the putative integrants. However, they were not visibly fluorescent when grown under inducing conditions. It was considered that this negative result might be due to the single copy nature of the integrated gfp gene in combination with the non-ideal growth temperature when inducing protein production at 42° C. Usually, the lambda cl^ts857/P_R/P_Lsystem is used to induce protein production in high copy number plasmid systems, with maximum protein yields usually obtained within 2-3 hours of switching to 42° C. However, with GFP being produced from only a single copy gene we considered that a time potentially much longer than 2-3 hours might be required to achieve visible levels of GFP, and that the 42° C. growth conditions might prevent continued expression of GFP to visible levels. Therefore, we considered that removal of the cl^ts857gene and the P_Rpromoter might allow unrepressed constitutive high-level expression of the GFP protein from the remaining P_Lpromoter. A simple deletion strategy was devised to test this hypothesis (see Example 2).

EXAMPLE 2

The temperature inducible gfp gene cassette integrated in E. coli resulted in non-fluorescing colonies. As discussed above, it was considered that a prolonged growth at the 42° C. induction temperature may have inhibited protein production in E. coli before detectable amounts of GFP could be produced from a single copy gfp gene. The following procedure was devised for the deletion of the cl^ts857gene from the plasmid to create an unrepressed (constitutively expressed) version of gfp gene cassette.

Generation of Unrepressed gfp Gene Cassette

Analysis of the nucleotide sequence of gfp gene cassette revealed a unique SmaI restriction enzyme that if used in combination with an EcoRV site in the pEntcIGFP plasmid (see FIG. 2C) would result in excision of most of the cl^ts857gene and P_Rfrom the cassette. Excision of the cl^ts857gene would effectively promote high-level constitutive transcription of gfp from the P_Lpromoter (see FIGS. 2C and 2D).
The pEntcIGFP plasmid containing the gfp gene cassette was restriction digested with SmaI and EcoRV (MBI Fermentas). The digested DNA was visualized by agarose gel electrophoresis and DNA corresponding to the vector minus excised cl^ts857gene was gel purified using a QIAquick gel extraction kit (Qiagen Inc). The digested DNA was ligated blunt-end using T4 DNA ligase (Roche) at 14° C. for 12 hr. The ligated DNA was used to transform chemically competent E. coli DH5 alpha cells, plated onto LB plates containing chloramphenicol and incubated overnight at 37° C. Positive colonies expressing GFP (following visual inspection under UV light) appeared on plates originating from a ligation of the mutant GFP gene cassette with the deleted cl^ts857repressor gene. The positive transformants were re-streaked to individual plates and singles colonies used for liquid cultures in LB medium containing chloramphenicol. After incubation overnight at 37° C., an aliquot from the culture was then used for plasmid extraction using QIAprep plasmid purification kit (Qiagen). Excision of the cl^ts857gene from the GFP gene cassette was confirmed after analysing an EcoRI restriction enzyme digest of the extracted plasmid by agarose gel electrophoresis. The plasmid containing the GFP gene cassette with the deleted cl^ts857gene was named pEntPLGFP, and the modified cassette is from herein referred as unrepressed GFP gene cassette.
Chromosomal Integration of Unrepressed GFP Gene Cassette into E. Coli and Salmonella Strains
Bacteriophage Mu DNA transposition complexes derived from pEntPLGFP was used for chromosomal integration of the unrepressed gfp gene cassette into E. coli and Salmonella strains. E. coli DH5 alpha and E. coli NCTC 12241 and E. coli NCTC 9001, and Salmonella typhyimurium and Salmonella abaetetuba cells were transformed as follows.
pEntPLGFP plasmid DNA was restriction digested with BglII (see FIG. 2). The resulting two restriction fragments were separated by gel electrophoresis and the DNA fragment comprising the Mu transposon and unrepressed mutant gfp gene cassette purified using a Qiaquick gel extraction kit (Qiagen).
Transpososome assembly reaction mixtures (20 μl) consisted of ˜6 pmol of MuA transposase (Finnzymes), 50% glycerol, 150 mM of Tris-HCl (pH 6.0), 150 mM NaCl, 0.1 mM EDTA, and 0.025% (v/v) Triton X-100, and ˜0.1 pmol to ˜0.9 pmol of pEntranceposon DNA containing the unrepressed gfp gene cassette.
Transpososome formation reactions were incubated at 30° C. for 2-3 hours, visualized on 2% agarose-TAE electrophoresis as described above and used for the transformation of E. coli NCTC 12241, E. coli NCTC 9001, Salmonella typhyimurium and Salmonella abaetetuba electrocompetent cells. Electrocompetent E. coli and Salmonella cells were all prepared and electroporated using the method described above. After electroporation 1 ml of SOC medium was added, incubated for 90 minutes, spread onto LB plates containing 25 μg/ml of chloramphenicol and incubated at 37° C. After 12 to 16 hours of growth at 37° C., colonies expressing the GFP protein could be easily visualized by illumination of plates with a hand held UV light.
As the gfpF0 primer binding site was deleted from the gfp gene cassette during deletion of the cl^ts857gene, a new oligonucleotide primer, gfpEnt 5′-CCAGTTTGCTCAGGCTCT-3′ (SEQ ID NO 19), was synthesized for PCR amplification the unrepressed gfp gene cassette. PCR amplification of the gfp cassette using gfpEnt and gfpR0 primers were performed using chloramphenicol resistant colonies obtained from electro-transformation with the unrepressed gfp cassette transpososome. Correct sized PCR products indicated the presence of the unrepressed gfp gene cassette in all tested colonies. Four positive colonies from each of each E. coli and Salmonella strains were selected and grown overnight in liquid media (LB+chloramphenicol). Genomic DNA was then extracted from the cells using a DNA extraction kit (Fast DNA, BIO 101 systems). PCR product amplified from genomic DNA from two different transformants of each E. coli and Salmonella strain was used for nucleotide sequencing. All sequencing results confirmed the presence of the unrepressed gfp gene cassette in the genomic DNA of both E. coli and Salmonella transformants. These transformants were clearly fluorescent when grown on a range of agar plates and illuminated with a UV light.

EXAMPLE 3

Identification of the Insertion Points of the Unrepressed gfp Gene Cassette into E. Coli and Salmonella Integrant Chromosomes
Genome walking PCR (GWPCR) was used for identification of the insertion points of the unrepressed gfp gene cassette into E. coli and Salmonella strains. Two genome walking primers were designed to walk upstream and downstream of the gfp gene cassette. Primer PENTGWF was used to genome walk from the 5′ end of the gfp gene cassette and GFPGWR to walk from the 3′ end of the cassette insertion point (See Table 1, FIGS. 2C and 2D).
Genomic walking PCRs and synthetic DNA linker assemblage were carried out according to the method described by Morris et al, Appl Environ Microbiol (1995) 61:2262-2269. The PENTGWF and GFPGWR primers were used in combination with primers complementary to the generic linker for GWPCR reactions. PCR products ranging from 300 bp to 800 bp were sequenced and results used for match searches in bacterial genomes database for identification of gfp gene cassette insertion points and flaking regions.
Insertion points of gfp gene cassette on the genomes of E. coli and Salmonella integrants were identified based on the published genome sequence data on Salmonella typhimurium and E. coli K12. For the fluorescent E. coli EC11775 strain, the gfp gene cassette was observed to be inserted into a gene encoding a homolog of E. coli K12 Zinc binding periplasmic protein (ZnaP). For the fluorescent E. coli BL21, the gfp gene cassette was inserted into a gene encoding 16S rRNA. For the fluorescent Salmonella abaetetuba, the gfp gene cassette was inserted into a gene homolog of S. typhimurium ATP-dependent helicase protein (hrpA). In the fluorescent Salmonella typhimurium, the gfp gene cassette was inserted into the sequence of a gene encoding a common antigen found in the outer membrane of Salmonella and other enterobacteria.

EXAMPLE 4

Generation of Fluorescent Listeria Monocytogenes

The strategy used to generate fluorescent Listeria monocytogens followed similar approach to that used for the E. coli and Salmonella strains. First, the gfp gene mut1 in an E. coli/Listeria shuttle vector pNF8 vector (Fortineau et al., 2000 Res Microbiol 151: 353-360) was replaced with our triple mutant gfp gene (gfp mut1 is a FACS optimized GFP with shifted excitation wavelength up to 488 nm). The gfp gene present in pEntPLGFP was amplified by PCR using the primers detailed in Table 3.

TABLE 3

		SEQ
		ID
Name	Sequence	NO

Gfpmutf1	5′-AAACGGGATCCGAAAGGAGGTTTATTAAAATGAG	24
	TAAAGGAGAAGAACTT

Gfpmutr1	5′-AAAAAACTGCAGTTATTTGTATAGTTCATCCATG	25
	CCA

The gfpmut1F primer was designed to introduce a BamHI restriction enzyme site and a consensus gram-positive ribosome binding site and the reverse gfpmt1R primer was designed to introduce a PstI site in the PCR products. The resulting PCR product and the pNF8 were digested with BamHI and PstI restriction enzymes (MBI Fermentas), ligated using T4 ligase (Roche) and used to transform chemically competent E. coli DH5α cells. Recombinant cultures harbouring the newly generated plasmid vector were recovered from selective LB agar plates containing 150 μ/mL of erythromycin (selective antibiotic resistance encoded in pNF8 vector). After incubation at 30° C. over 72 hr visibly green colonies appeared on plates (GFP expression in those recombinant clones in driven by the Listeria Pdlt promoter located just upstream of the gfp gene in the vector). Three putative recombinant clones were streaked onto fresh LB+erythromycin plates and single colonies used to inoculate LB+erythromycin liquid media followed by overnight incubation at 37° C. with shaking. In order to verify if the isolated pNF8 plasmid was carrying our triple mutant gfp gene and not the original FACS optimized GFP gfp gene mut1, an aliquot of the cultures were used for fluorescence assay measurements using a FLUOstar fluorimeter (BMG Lab Technologies GmbH). Two different excitation wavelengths—360 nm and 480 nnm with fixed 520 nm emission were tested. Results showed high fluorescence from cells bearing the original pNF8 plasmid at 480 nm and lower fluorescence at 360 nm excitation, whereas opposite results for cells bearing the recombined triple mutant gfp with high fluorescence at 360 nm and lower fluorescence at 480 nm. One selected recombinant bearing the reconstructed vector named pNFMT1 was used for inoculation of LB liquid media containing 150 μl/mL erythromycin and incubated overnight at 37° C. The culture obtained was used for plasmid extraction using QIAprep kit (Qiagen).

L. monocytogenes electrocompetent cells were prepared by growing 250 ml of culture in brain and heart infusion (BHI) media containing 0.5 M of sucrose with shaking at 37° C. to optical density measured at 600 nm of 0.2. Penicillin was then added to 10 μl/ml and the culture grown to optical density measured at 600 nm of 0.5. Cells were cooled on ice and harvested by centrifugation at 4° C. and resuspended in 100 ml of ice cold 0.5 M sucrose in 1 mM HEPES pH 7.0 three times consecutively, then resupended in 1 ml of ice cold 0.5 M sucrose in 1 mM HEPES pH 7.0, and stored as 50 μl aliquots at −80° C. Transformation efficiency of L. monocytogenes electrocompetent cells was evaluated using the pNFMT1 vector. Enumeration of fluorescent L. monocytogenes colonies LB agar plates containing 150 μL/mL of erythromycin indicated transformation efficiencies up to 10̂5 c.f.u. per μg of pNFMT1 DNA.
The Pdlt promoter-mutant gfp gene construct present in the pNFMT1 was excised from the vector by restriction digest using EcoRI and Hind III restriction enzymes (MBI Fermentas). The pEntranceposon vector (Finnzymes) was also digested with EcoRI and Hind III restriction enzymes (MBI Fermentas). DNA corresponding to the digested Pdlt promoter-mutant gfp gene and the digested pEntranceposon vector were separated by agarose gel electrophoresis and purified from gels using a QIAquick gel extraction kit (Qiagen). The digested DNA was used for ligation using T4 ligase (Roche) for generation of the plasmid vector pEnt-Pdlt-GFPMT1. The pEnt-Pdlt-GFPMT1 vector was then used to transform competent E. coli DH5α cells. Recombinant cultures harbouring the vector pEnt-Pdlt-GFPMT1 were recovered from selective LB agar plates containing 25 μl/ml of chloramphenicol (selective antibiotic resistance encoded in pEnt-Pdlt-GFPMT1 vector).
The pEnt-Pdlt-GFPMT1 vector was digested with BglII restriction enzyme and the excised CamR transposon fragment containing the Pdlt-gfp separated by agarose gel electrophoresis and purified using a QIAquick gel Extraction kit (Qiagen Inc). Purified CamR Pdlt-gfp transposon DNA was used for transpososome assembly reactions. Transpososome formation reactions were optimized by titration of the amount of CamR Pdlt-gfp gene transposon DNA against a fixed amount of MuA transposase enzyme (Finnzymes). Reagents for transpososome assembly reaction mixtures (20 μl) included ˜6 pmol of MuA transposase, 50% glycerol, 150 mM of Tris-HCl (pH 6.0), 150 mM NaCl, 0.1 mM EDTA, and 0.025% (v/v) Triton X-100. Transpososome reactions were performed by adding ˜0.25 pmol to ˜1.0 pmol of Pdlt-gfp gene transposon DNA to the mixtures followed by incubating at 30° C. for 2-3 hours. Transpososome formation was visualized by electrophoresis on 2% agarose-TAE buffer gel containing 80 μg/ml of bovine serum albumen. Transpososome assembly reaction samples (1 μl) were loaded into the gel using 0.2 (v/v) of Ficoll 400 as loading buffer. After gel visualization, selected transpososome complexes were used for the transformation of L. monocytogenes electrocompetent cells. Aliquots of 1 μl of transpososome reactions were used for electroporation of 40 μl electrocompetent L. monocytogenes cells using a Genepulser (Bio-Rad) at the following settings: voltage 2.5 kV; capacitance 25 μF; resistance 200Ω (Bio-Rad 2-mm electrode spacing cuvettes). After electroporation 1 ml of BHI medium was added, incubated for 90 minutes, spread onto LB plates containing 25 μg/ml of chloramphenicol and incubated at 30° C.

EXAMPLE 5

This section describes the expression of another fluorescent protein, a red fluorescent protein known as DsRed2, in E. coli. The Dsred2 was successfully integrated onto the chromosome of E. coli but no fluorescence was visible when examined under a UV light.

E. Coli Containing Red Fluorescent Protein on a Plasmid

A gene cassette was constructed by placing T7 promoter and ribosomal binding site upstream of starting codon of DsRed2 gene (Clontech) using the primers T7promppf1 and Rfppr1 (see Table 1). The cassette, herein referred to as the T7DsRed2 gene cassette, was constructed then ligated into the pEntranceposon plasmid (Finnzymes). This plasmid was subsequently transformed into E. coli DH5 alpha cells.
Colonies of the plasmid containing E. coli showed a bright red fluorescence after two days of growth on agar containing chloramphenicol. Only weak fluorescence was observed after 24 hours growth.

Chromosomal Integration of Red Fluorescent Protein in E. Coli

The pEntranceposon-CmR plasmid containing the T7-DsRed2 gene cassette was digested by BglII restriction enzyme digest and the released transposon used for MuA transpososome formation (Finnzymes). Aliquots of the transpososome formation were used for transformation of electrocompetent E. coli BL21 (DE3) cells and chloramphenicol resistant transformants were recovered after incubation on plates for 18-24 hours at 37° C. Four transformants were isolated, chromosomal DNA extracted and analyzed for incorporation of T7DsRed2 gene into the chromosome by PCR. Results were positive for the clones tested, indicating the incorporation of T7DsRed2 gene into the genome of cultures. For one of the clones nucleotide sequencing was performed and the T7DsRed2 gene sequence was confirmed to be intact. Transformants were cultured under inducing conditions on media containing 1 mM IPTG, an inducer of transcription from the T7 promoter. However, no DSRed2 fluorescence could be detected from cultures when plates were illuminated with UV light.

EXAMPLE 6

Stability of Fluorescent Strains

The fluorescence of the E. coli, Listeria and Salmonella integrant strains were examined to ensure that these organisms remained fluorescent when passaged multiple times.
Yeast extract broth was inoculated with each of the fluorescent E. coli and Salmonella strains. A broth of Brain Heart Infusion (Oxoid) was inoculated with the fluorescent Listeria strain. The cultures were incubated with shaking at 37° C. for 24 hours. A loopfull of culture was then streaked onto nutrient agar or in the case of Listeria onto blood agar and incubated at 37° C. for 24 hours. The plates were then illuminated with a UV light and carefully examined for the presence of non-fluorescent colonies.
A colony from each plate was then used to inoculate another broth and the entire process was repeated. This continued for 10 rounds of culturing.
No non-fluorescent colonies were observed. An atypical fluorescent colony was observed with the Salmonella abatetuba culture. The colony appeared less smooth and flatter than the normal colonies for this strain. Biochemical analysis revealed that it was Salmonella abatetuba but a mutant that formed atypical colonies. It is likely that the repeated exposure to UV light caused the mutation. The mutant was still fluorescent.
These results demonstrate that the fluorescence gene is highly stable in these strains of bacteria.

SUMMARY

The present inventors have determined that three select modifications to the GFP protein, namely S72A, M153T and V163A, result is consistently higher visible expression of the protein when expressed in E. coli in a plasmid.
It has been determined that using the unrepressed lambda P_Lpromoter, it is possible to constitutively express visibly detectable levels of the modified form of GFP from a single copy of the gfp gene integrated into the genome of 3 different strains of E. coli and two species of Salmonella. Initial experiments indicated that expression was stable through long periods of growth and cell division. Precise genomic integration points were determined for each of the E. coli and Salmonella gfp-cassette integrants.
Detectable levels of the modified GFP were observed when expressed in Listeria monocytogenes under the control of the Listeria Pdlt promoter.
Detectable levels of the modified GFP were not observed when expressed from a single copy integrated gene under the control of the lambda ci^ts857repressor protein. Similarly, the fluorescent protein DsRed2 could not be detected when expressed from a single copy integrated gene under the control of a T7 RNA polymerase/T7 promoter system.
Means for the production of cells visibly altered by expression of a modified GFP protein have been developed that make them useful as QC strains in microbiological testing.
It should be appreciated that this technique is applicable to other bacterial species, and that other promoter systems and marker genes could be used in a similar fashion to achieve visible alteration of bacterial cells.
It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

Claims

1-24. (canceled)

25. An isolated mutated green fluorescent protein (gfp) gene having mutations at nucleotides positions 1492, 1493 (Ser72Ala), 1737 (Met153Thr) and 1766 (Val163Ala) in the wild-type gfp gene as set out in SEQ ID NO 1, or mutations for synonymous codons which change the same amino acid positions (Ser72Ala, Met153Thr and Val163Ala).

26. The isolated gene of claim 25 having a nucleic acid sequence from bases 1524 to 2240 as set out in SEQ ID NO 4.

27. An isolated green fluorescent protein (GFP) expressed by the mutated gfp gene according to claim 25.

28. The isolated mutant GFP according to claim 25 comprising one or more mutations of mutant GFP01, mutant GFP02, mutant GFP03, mutant GFP07, mutant GFP10, mutant GFP15, mutant GFP16, mutant GFP20, mutant GFP21, mutant GFP22, mutant GFP26, mutant GFP27, mutant GFP37, mutant GFP43, mutant GFP44, mutant GFP53, mutant GFP54, or mutant GFP55.

29. The isolated mutant GFP according to claim 27 comprising mutant GFP01, mutant GFP02, mutant GFP03, mutant GFP07, mutant GFP10, mutant GFP15, mutant GFP16, mutant GFP20, mutant GFP21, mutant GFP22, mutant GFP26, mutant GFP27, mutant GFP37, mutant GFP43, mutant GFP44, mutant GFP53, mutant GFP54, or mutant GFP55.

30. The isolated mutant GFP according to claim 29 having an amino acid sequence as set out in SEQ ID NO 6.

31. A bacterium or cell containing the mutated gfp gene according to claim 25.

32. The bacterium according to claim 31 selected from the group consisting of Acinetobacter lwoffii, Aeromonas hydrophila, Aspergillus niger, Bacillus cereus, Bacillus subtilis, Campylobacter coli, Campylobacter jejuni, Candida albicans, Citrobacter freundii, Clostridium perfringens, Clostridium sporogenes, Edwardsiella tarda, Enterobacter aerogenes, Enterobacter cloacae, Enterococcus faecalis, Escherichia coli, Escherichia coli 0157, Haemophilus influenzae, Klebsiella pneumoniae, Klebsiella aerogenes, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus fermentus, Legionella pneumophila, Listeria innocua, Listeria ivanovii, Listeria monocytogenes, Meth. Resist. Staph. Aureus, Neisseria gonorrhoeae, Proteus rettgeri, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Pseudomonas cepacia, Pseudomonas fluorescens, Rhodococcus equi, Salmonella abaetetuba, Saccharomyces cerevisiae, Salmonella salford, Salmonella menston, Salmonella sofia, Salmonella Poona, Salmonella typhimurium, Salmonella poona, Serratia marcescens, Shigella sonnei, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes, Vibrio parahaemolyticus, Yersinia enterocolitica, and Zygosaccharomyces rouxii.

33. The bacterium according to claim 32 being Escherichia coli, Salmonella sp or Listeria sp.

34. The bacterium according to claim 33 wherein the Salmonella sp is Salmonella typhimurium or Salmonella abaetetuba and the Listeria sp is L. monocytogenes.

35. The cell according to claim 31 comprising Candida albicans, Zygosaccharomyces rouxii or Aspergillus niger.